Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC–MS/MS
- 1 September 2015
- journal article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 28 (1), 513-520
- https://doi.org/10.1016/j.intimp.2015.07.007
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-AnalysisThe American Journal of Gastroenterology, 2013
- Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohnʼs diseaseInflammatory Bowel Diseases, 2012
- The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologistsClinical Rheumatology, 2012
- General LC-MS/MS Method Approach to Quantify Therapeutic Monoclonal Antibodies Using a Common Whole Antibody Internal Standard with Application to Preclinical StudiesAnalytical Chemistry, 2012
- Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2011
- An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regionsAnalytical and Bioanalytical Chemistry, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseThe New England Journal of Medicine, 2010
- Towards Absolute Quantification of Therapeutic Monoclonal Antibody in Serum by LC−MS/MS Using Isotope-Labeled Antibody Standard and Protein Cleavage Isotope Dilution Mass SpectrometryAnalytical Chemistry, 2008
- Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006